Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Items 1,101–1,200 of 2,932
Pinder, C., Lebedinec, R., Levine, T. P., Birch, M., & Oliver, J. D. (2023) · PLoS ONE · doi:10.1371/journal.pone.0289441 · Cited by 12
Fungal infections in Sudan: An underestimated health problem
Ahmed, S. A., Ismail, M., Albirair, M. T., Nail, A. M. A., & Denning, D. W. (2023) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0011464 · Cited by 15
Self-citationBilal, H., Zhang, D., Shafiq, M., Khan, M. N., Chen, C., Khan, S., Cai, L., Khan, R. U., Hu, H., & Zeng, Y. (2023) · Epidemiology and Infection · doi:10.1017/s095026882300167x · Cited by 13
“A study in 2017 reported global estimates of 3,000,000 cases of chronic pulmonary aspergillosis, and ~ 250,000 cases of invasive aspergillosis [4].”
BackgroundAwassa, J., Soulé, S., Cornu, D., Ruby, C., & El‐Kirat‐Chatel, S. (2024) · Nanoscale · doi:10.1039/d3nr06027f · Cited by 13
Touil, N., Lakoud, S. G., Boukachabia, M., et al. (2024) · ChemistrySelect · doi:10.1002/slct.202303808 · Cited by 11
Chowdhury, M. G., Kalmegh, V., Kapoor, S., et al. (2024) · RSC Medicinal Chemistry · doi:10.1039/d3md00718a · Cited by 11
Cissé, O. H., Ma, L., & Kovacs, J. A. (2024) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00202-22 · Cited by 12
“An immunosuppressed mouse exposed to these mice invariably develops full-blown PCP (17, 50).”
BackgroundInfluentialGoughenour, K. D., Creech, A., Xu, J., He, X., Hissong, R., Giamberardino, C. D., Tenor, J. L., Toffaletti, D. L., Perfect, J. R., & Olszewski, M. A. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1392015 · Cited by 12
Arendrup, M. C., Armstrong-James, D. P. H., Borman, A. M., Denning, D. W., Fisher, M. C., Gorton, R., Maertens, J. A., Martín‐Loeches, I., Mehra, V., Mercier, T., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae372 · Cited by 15
“A lack of research funding to tackle these challenges or update epidemiological data has not helped [1, 115, 120].”
InfluentialSelf-citationSong, W., Wang, N., Li, A., Ji, X., Huang, X., Wang, T., & Hao, H. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03748-5 · Cited by 10
“Recent global estimates have found that nearly 1 billion people suffer from skin, nail and hair fungal infections, and more than 150 million people suffer from severe fungal diseases that not only affect people's lives, but can even be life-threatening [8].”
Shah, S., Lai, J., Basuli, F., Martínez‐Orengo, N., Patel, R., Turner, M. L., Wang, B., Shi, Z.-D., Sourabh, S., Peiravi, M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adl5934 · Cited by 13
Navigating the fungal battlefield: cysteine-rich antifungal proteins and peptides from Eurotiales
Holzknecht, J., & Marx, F. (2024) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2024.1451455 · Cited by 15
MLAFP-XN: Leveraging neural network model for development of antifungal peptide identification tool
Sultan, M. F., Shaon, M. S. H., Karim, T., Ali, M. M., Hasan, M. Z., Ahmed, K., Bui, F. M., Chen, L., Dhasarathan, V., & Moni, M. A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37820 · Cited by 13
“This infection is spreading rapidly, and it is noted that billions of people are injured by a fungal infection [1 – 3].”
BackgroundCurrent and emerging technologies to develop Point-of-Care Diagnostics in medical mycology
Matsuo, T., Wurster, S., Hoenigl, M., & Kontoyiannis, D. P. (2024) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2024.2397515 · Cited by 12
“Recent data estimate that over 13 million individuals suffer from severe fungal diseases, resulting in a substantial 1.5 million deaths globally each year [8].”
InfluentialThe activating receptor NKG2D is an anti-fungal pattern recognition receptor
Charpak‐Amikam, Y., Kournos, M., Kotzur, R., Isaacson, B., Brenner, T. B., Gomez-Cesar, E., Abou-Kandil, A., Ben‐Ami, R., Korem, M., Guerra, N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52913-2 · Cited by 17
Invasive Fungal Infections in Immunocompromised Conditions: Emphasis on COVID-19
Kaur, M., Thakur, P., Verma, N., Choksket, S., Harshvardhan, Korpole, S., Devadatha, B., & Grover, V. (2024) · Current Microbiology · doi:10.1007/s00284-024-03916-1 · Cited by 13
“The risk factors for invasive fungal infections include diverse host and environmental conditions, which remain varied among developed and developing nations [4].”
Deivarajan, H. R., SethupathyR, P., Elamurugan, V., et al. (2024) · Ophthalmology Retina · doi:10.1016/j.oret.2024.11.003 · Cited by 11
Infection and pulmonary vascular diseases consortium: United against a global health challenge
Oliveira, S. D., Almodóvar, S., BUTROUS, G. S., Pérez, V. D. J., Fabro, A. T., Graham, B. B., Mocumbi, A. O., Nyasulu, P. S., Tura-Ceide, O., Oliveira, R. K. F., et al. (2024) · Pulmonary Circulation · doi:10.1002/pul2.70003 · Cited by 10
Metcalf, R., Akinbobola, A., Woodford, L., & Quilliam, R. S. (2025) · Environmental Science and Pollution Research · doi:10.1007/s11356-025-36558-2 · Cited by 13
“One of the most important fungal infections is invasive candidiasis, caused by several species of the yeast Candida , with an estimated 700,000 cases annually (Bongomin et al. 2017).”
Gunawan, U., Ibrahim, S., Ivansyah, A. L., et al. (2025) · RSC Advances · doi:10.1039/d5ra03211c · Cited by 11
Direct Visualization of Fungal Burden in Filamentous Fungus-Infected Silkworms
Yu, Y., Wolf, A., Thusek, S., Heinekamp, T., Bromley, M., Krappmann, S., Terpitz, U., Voigt, K., Brakhage, A. A., & Beilhack, A. (2021) · Journal of Fungi · doi:10.3390/jof7020136 · Cited by 13
Zhang, Y., Fang, W., Raimi, O. G., Lockhart, D. E. A., Ferenbach, A. T., Lü, L., & van Aalten, D. M. F. (2021) · Molecular Microbiology · doi:10.1111/mmi.14706 · Cited by 11
Antifungal Activity of the Sesquiterpene Lactones from Psephellus bellus
Nawrot, J., Adamski, Z., Kamińska-Kolat, B., Kubisiak-Rzepczyk, H., Kroma, A., Nowak, G., & Gornowicz‐Porowska, J. (2021) · Plants · doi:10.3390/plants10061180 · Cited by 11
Courtship Ritual of Male and Female Nuclei during Fertilization in Neurospora crassa
Brun, S., Kuo, H.-C., JEFFREE, C. E., Thomson, D. D., & Read, N. D. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00335-21 · Cited by 14
The SAGA and NuA4 component Tra1 regulates Candida albicans drug resistance and pathogenesis
Razzaq, I., Berg, M. D., Jiang, Y., Genereaux, J. L., Uthayakumar, D., Kim, G. H., Agyare-Tabbi, M. R., Halder, V., Brandl, C. J., Lajoie, P., et al. (2021) · Genetics · doi:10.1093/genetics/iyab131 · Cited by 11
Marine Compounds with Anti-Candida sp. Activity: A Promised “Land” for New Antifungals
Alves, A. M. C. V., Martins, N. A., & Rodrigues, C. F. (2022) · Journal of Fungi · doi:10.3390/jof8070669 · Cited by 13
Synthesis and Antifungal Activity of Some Novel Coumarin‐Amino Acid Conjugates
Tiwari, N., Kumari, A., Uttam, G., Singh, V., Singh, K., & Katiyar, D. (2022) · ChemistrySelect · doi:10.1002/slct.202201299 · Cited by 11
van Wijlick, L., Znaidi, S., Hernández-Cervantes, A., Basso, V., Bachellier‐Bassi, S., & d’Enfert, C. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.960884 · Cited by 13
“albicans and related Candida species are the main cause of invasive fungal infections (Brown et al., 2012; Bongomin et al., 2017).”
BackgroundThe Anticancer Drug Bleomycin Shows Potent Antifungal Activity by Altering Phospholipid Biosynthesis
Pokharel, M., Konarzewska, P., Roberge, J. Y., Han, G., Wang, Y., Carman, G. M., & Xue, C. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00862-22 · Cited by 14
Cinematic reflectometry using QIKR, the quite intense kinetics reflectometer
Ankner, J. F., Ashkar, R., Browning, J. F., Charlton, T. R., Doucet, M., Halbert, C. E., Islam, F. F., Karim, A., Kharlampieva, E., Kilbey, S. M., et al. (2023) · Review of Scientific Instruments · doi:10.1063/5.0122279 · Cited by 11
Wang, Y., Wang, K., Rivera, A., & Xue, C. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04955-22 · Cited by 15
de Souza, P. C., Corrêa, A. E. D. N., Gameiro, J. G., de Oliveira, A. G., Panagio, L. A., Venâncio, E. J., & Almeida, R. S. (2023) · Microbial Pathogenesis · doi:10.1016/j.micpath.2023.106166 · Cited by 11
Characterization and Antifungal Activity of Chlorhexidine:β-cyclodextrin Inclusion Complexes
Schoeffel, A. C., Morikava, F. S., Urban, A. M., Novatski, A., Moraes, G. S., Matioli, G., Ferrari, P. C., Neppelenbroek, K. H., Farago, P. V., & Urban, V. M. (2023) · Therapeutic Delivery · doi:10.4155/tde-2022-0068 · Cited by 11
Elgammal, Y., Salama, E. A., & Seleem, M. N. (2023) · Medical Mycology · doi:10.1093/mmy/myad081 · Cited by 16
Herbal drugs-loaded soft nanoparticles for treating skin disorders: Where do we stand?
Reolon, J. B., Sari, M. H. M., Marchiori, C., Dallabrida, K. G., dos Santos, J. A. R., de Almeida, I. D. F. R., Alves, F. M. S., Bonini, J. S., & Ferreira, L. M. (2023) · Industrial Crops and Products · doi:10.1016/j.indcrop.2023.117602 · Cited by 15
Convergent evolution of innate immune-modulating effectors in invasive fungal pathogens
Boucher, M. J., & Madhani, H. D. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.10.011 · Cited by 10
“Invasive fungal infections cause 1.5 million deaths each year, with effective treatment challenged by poor diagnostics and limited therapeutic options [1,2].”
BackgroundInfluentialLiu, Z., Chen, H., Chen, D., Wu, X., Xu, H., Chen, P., Wang, R., & Chen, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-67174-8 · Cited by 13
Pbp1-Interacting Protein Mkt1 Regulates Virulence and Sexual Reproduction in Cryptococcus neoformans
Son, Y.-E., Fu, C., Jung, W. H., Oh, S., Kwak, J., Cardenas, M. E., Heitman, J., & Park, H.-S. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00355 · Cited by 11
“Cryptococcus is the leading cause of adult meningoencephalitis in Sub-Saharan Africa and Southeast Asia and is associated with a high mortality rate (Armstrong-James et al., 2014; Bongomin et al., 2017; Rajasingham et al., 2017).”
BackgroundCurrent burden of serious fungal infections in Republic of Congo
Amona, F. M., Denning, D. W., Moukassa, D., & Hennequin, C. (2020) · Mycoses · doi:10.1111/myc.13075 · Cited by 15
“There are some reports on PjP in RoC(15,40,41) 23 but overall the disease is poorly described in the country.”
BackgroundSelf-citationStauber, R. H., Westmeier, D., Wandrey, M., Becker, S., Docter, D., Ding, G., Thines, E., Knauer, S. K., & Siemer, S. (2020) · Nanotoxicology · doi:10.1080/17435390.2020.1808251 · Cited by 12
Shelton, J., Fisher, M. C., & Singer, A. C. (2020) · Citizen Science Theory and Practice · doi:10.5334/cstp.325 · Cited by 20
Janssen, N. A. F., Brüggemann, R. J. M., Reijers, M. H. E., Henriet, S., ten Oever, J., de Mast, Q., Berk, Y., de Kort, E., Kullberg, B. J., Netea, M. G., et al. (2020) · Journal of Fungi · doi:10.3390/jof6040274 · Cited by 12
“First, it may reflect an until recently under-recognized prevalence of this chronic infection [2].”
BackgroundEpidemiology of aspergillosis in hospitalised Spanish patients—A 21‐year retrospective study
González-García, P., Alonso‐Sardón, M., López‐Bernús, A., Carbonell, C., Romero‐Alegría, Á., Muro, A., Galindo‐Pérez, I., Bellido, J. L. M., Pardo‐Lledías, J., & Belhassen‐García, M. (2021) · Mycoses · doi:10.1111/myc.13239 · Cited by 10
Nanomaterials for skin antifungal therapy: An updated review
Nagpal, M., & Kaur, M. (2021) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2021.11s102 · Cited by 19
“5 lakh of invasive Aspergillosis, 5 lakh cases of Pneumocystis jirovecii pneumonia, 1 lakh case reports of disseminated Histoplasmosis, over 100 lakh case reports of fungal asthma, and around 10 lakh case reports of fungal Keratitis occur annually (Bongomin et al., 2017).”
BackgroundInfluentialRana, A., Gupta, N., & Thakur, A. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101017 · Cited by 11
AHMAD, M. A., LIM, Y. H., Chan, Y. S., et al. (2021) · Acta Pharmaceutica · doi:10.2478/acph-2022-0013 · Cited by 11
“Also, infections of various origins are among the major contributors to global morbidity and mortality (8, 9).”
Novel Clinical and Laboratorial Challenges in Aspergillosis
Sabino, R., & Veríssimo, C. (2022) · Microorganisms · doi:10.3390/microorganisms10020259 · Cited by 11
“Global estimates have indicated that there are approximately 250,000 cases of invasive aspergillosis (IA) annually [1].”
BackgroundFocused library of phenyl-fused macrocyclic amidinoureas as antifungal agents
Balestri, L. J. I., D’Agostino, I., Rango, E., Vagaggini, C., Marchitiello, R., Mariotti, M., Casian, A., Deodato, D., Truglio, G. I., Orofino, F., et al. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10388-7 · Cited by 12
Cutaneous disseminated sporotrichosis in immunocompetent patient: Case report and literature review
Queiroz‐Telles, F., Cognialli, R. C. R., Salvador, G. L. D. O., et al. (2022) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2022.05.003 · Cited by 11
“Sporotrichosis is the most prevalent implantation mycosis in the world, considered a neglected endemic mycosis, with a global estimate of 40,000 new cases per year [1,2].”
BackgroundZouirech, O., Alajmi, R. A., jeddab, H. E., Allali, A., Bourhia, M., Moussaoui, A. E., Barnossi, A. E., Ahmed, A. M., Giesy, J. P., Aboul‐Soud, M. A. M., et al. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/4675016 · Cited by 12
“Aromatic and medicinal plants are a source of chemical molecules resulting from secondary metabolism, belonging to diverse chemical classes, such as alkaloids, phenols, flavonoids, terpenoids, and steroids [13, 14].”
BackgroundRetrospective Analysis of Tinea Capitis in Xinjiang, China
Wang, X., Abuliezi, R., Hasimu, H., Zhang, L., & Abliz, P. (2023) · Mycopathologia · doi:10.1007/s11046-022-00702-0 · Cited by 11
Fungal, Viral, Multicelled Parasitic, and Protozoan Infections
Grauer, A. L., & Roberts, C. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-809738-0.00012-0 · Cited by 15
Pereira, R., Pereira, A. L., Ferreira, M. M., Fontenelle, R. O. D. S., Saker‐Sampaio, S., dos Santos, H. S., Bandeira, P. N., de Vasconcelos, M. A., Queiroz, J. Á. N., Braz‐Filho, R., et al. (2019) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201920180204 · Cited by 13
“On the other hand, although the epidemiology of fungal diseases has changed over the past few decades, Candida species continue to be the main fungal pathogens responsible for most cases of severe fungal disease, such as candidiasis (Bongomin et al. 2017).”
BackgroundGenome Sequences of Two Strains of the Food Spoilage Mold Aspergillus fischeri
Zhao, S., Latgé, J., & Gibbons, J. G. (2019) · Microbiology Resource Announcements · doi:10.1128/mra.01328-19 · Cited by 9
Antifungal pipeline: Is there light at the end of the tunnel?
Schinas, G., Spernovasilis, N. A., & Akinosoglou, K. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i16.2686 · Cited by 13
Naskar, S., Prajapati, A., & Kaur, R. (2025) · FEMS Yeast Research · doi:10.1093/femsyr/foaf025 · Cited by 17
“Inv asiv e fungal infections are associated with high morbidity and mortality in hospitals worldwide, with ∼ 2.5 million people dying of these infections e v ery year (Bongomin et al. 2017 , Denning 2024 ).”
InfluentialWoods, M., Bermas, A., Ball, B., Muselius, B., Chan, N., Gutierrez‐Gongora, D., Ramezanpour, S. S., McAlister, J. A., Sieber, S. A., & Geddes‐McAlister, J. (2025) · Nature Communications · doi:10.1038/s41467-025-61412-x · Cited by 10
“The burden of fungal disease ranges from mild infections to life-threatening systemic mycoses, impacting millions of people on an annual basis 1 .”
Antimicrobial Potential of Bee-Derived Products: Insights into Honey, Propolis and Bee Venom
Grinn‐Gofroń, A., Kołodziejczak, M., Hrynkiewicz, R., Lewandowski, F., Bębnowska, D., Adamski, C., & Niedźwiedzka‐Rystwej, P. (2025) · Pathogens · doi:10.3390/pathogens14080780 · Cited by 24
“Fungi are ubiquitous in the environment and an estimated 3–5 million species are able to cause disease in humans [117].”
InfluentialThe dual role of azoles: lifesaving antifungals and drivers of resistance – a One Health perspective
Roohi, B., Tyndall, J. D. A., Svoboda, T., de Hoog, S., Crous, P. W., Monk, B. C., Strobl, B., Weißenbacher, A., Strauss, J., Verweij, P. E., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71762-9 · Cited by 15
Zhang, K., Hu, Y., Li, R., & Li, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.966814 · Cited by 18
“Systemic fungal infection remains a major health threat leading to high morbidity and mortality rates in immunocompromised patients, including those who are receiving immune-suppressive drug treatment or chemotherapy, or with pre-existing infections or malignant diseases (1, 2).”
BackgroundRadiometal chelators for infection diagnostics
Akter, A., Lyons, O., Mehra, V., Isenman, H. L., & Abbate, V. (2023) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2022.1058388 · Cited by 11
“On the other hand, the global burden of Invasive Fungal Infections (IFI) is less well established, but may lead to a “ silent crisis ” with over 150 million cases of IFI estimated annually worldwide, resulting in approximately 1.7 million annual deaths (10).”
BackgroundInfluentialTestempasis, S., & Karaoglanidis, G. S. (2023) · Journal of Fungi · doi:10.3390/jof9020221 · Cited by 12
“Even though there are numerous studies aiming to determine the fungicide sensitivity profile of important grapevine pathogens such as Plasmopara viticola, Erysiphe necator, or Botrytis cinerea [18,21], the information regarding the fungicide sensitivity status of black aspergilli populations originating from vineyards…”
BackgroundA Comprehensive Review of Identification Methods for Pathogenic Yeasts: Challenges and Approaches
Morovati, H., Kord, M., Ahmadikia, K., Eslami, S., Hemmatzadeh, M., Kurdestani, K. M., Khademi, M., & Darabian, S. (2023) · Advanced Biomedical Research · doi:10.4103/abr.abr_375_22 · Cited by 12
“considered the most frequent fungi isolated from patients with malignancy,[110,116,117] the second causative agent of”
BackgroundCosta‐Barbosa, A., Pacheco, M. I., Carneiro, C., Botelho, C., Gomes, A. C., Oliveira, M. E. C. D. R., Collins, T., Vilanova, M., Pais, C., Correia, A., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115362 · Cited by 14
Liu, L., Wu, H., Long, Y., Yang, X., Du, C., Xu, Y., & Ji, Q. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115777 · Cited by 10
Utilization of Raman spectroscopy for identification and characterization of fungal pathogens
Udupa, R., Yegneswaran, P. P., Lukose, J., et al. (2023) · Fungal Biology Reviews · doi:10.1016/j.fbr.2023.100339 · Cited by 10
Candida haemulonii Species Complex: Emerging Fungal Pathogens of the Metschnikowiaceae Clade
Cao, C., Bing, J., Liao, G., Nobile, C. J., & Huang, G. (2023) · Zoonoses · doi:10.15212/zoonoses-2023-0021 · Cited by 9
“Candida albicans is the most frequently isolated Candida species in clinical settings, and thus has received substantial research attention [3,10].”
BackgroundInfluentialMendoza, B. J., Zheng, X., Clements, J. C., Cotter, C. J., & Trinh, C. T. (2023) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.3c00342 · Cited by 12
“as well as an increase in geographic range and dispersal due to climate change (4, 5).”
BackgroundAnti‐Candida activity and in vitro toxicity screening of antifungals complexed with β‐cyclodextrin
Moraes, G. S., Tozetto, N. M., Pedroso, T. A. A., de Mattos, M. A., Urban, A. M., Paludo, K. S., dos Santos, F. A., Neppelenbroek, K. H., & Urban, V. M. (2024) · Journal of Applied Toxicology · doi:10.1002/jat.4575 · Cited by 10
Asgaonkar, K. D., Patil, S. M., Chitre, T. S., Prabhu, A., Shevate, K. S., Sagar, A. K., & Naik, A. P. (2024) · Anti-Infective Agents · doi:10.2174/0122113525279683231228130206 · Cited by 13
de Oliveira, H. C., Santos, M. D. M., Camillo-Andrade, A. C., Castelli, R. F., Reis, F. C. G., Carvalho, P. C., & Rodrigues, M. L. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107157 · Cited by 9
Khalifa, H. O., Watanabe, A., & Kamei, K. (2024) · Mycopathologia · doi:10.1007/s11046-024-00847-0 · Cited by 11
“Fungal illnesses are estimated to afflict over a billion people each year and cause 1.5 million deaths worldwide [1], a figure comparable to tuberculosis and more than three times that of malaria [2].”
InfluentialStrategies of Pharmacological Repositioning for the Treatment of Medically Relevant Mycoses
Gómez-Gaviria, M., Contreras-López, L. M., Aguilera-Domínguez, J. I., & Mora-Montes, H. M. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s466336 · Cited by 12
McMullan, B. J., Kim, H. Y., Alastruey‐Izquierdo, A., Tacconelli, E., Dao, A., Oladele, R. O., Tanti, D., Govender, N. P., Shin, J. H., Heim, J., et al. (2024) · Medical Mycology · doi:10.1093/mmy/myae038 · Cited by 16
“14 , 15 Pneumocystis jirovecii is one of a number of important fungal pathogens, causing in excess of 1.6 million global deaths each year.”
BackgroundInfluentialSelf-citationDesign of Proteolytic-Resistant Antifungal Peptides by Utilizing Minimum d -Amino Acid Ratios
Lai, Z., Yuan, X., Chen, W., Chen, H., Li, B., Bi, Z., Lyu, Y., & Shan, A. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00394 · Cited by 13
Maertens, J. A., Slavin, M. A., Hoenigl, M., Thompson, G. R., Richardson, M. D., & Lass‐Flörl, C. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae158 · Cited by 14
Navigating treatment for basidiobolomycosis: a qualitative review of 24 cases
Pouladfar, G., Jahangiri, S., Shahpar, A., et al. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09664-8 · Cited by 10
Mechanism of action and synergistic effect of Eugenia uniflora extract in Candida spp.
de Souza, L. B. F. C., Bento, A. D. O., Lourenço, E. M. G., Ferreira, M. R. A., de Oliveira, W. N., Soares, L. A. L., Barbosa, E. G., Rocha, H. A. O., & Chaves, G. M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303878 · Cited by 13
“Recent global estimates have suggested that approximately 700,000 cases of invasive candidiasis occur annually [26].”
BackgroundCrotti, S., Cruciani, D., Sabbatucci, M., Spina, S., Piscioneri, V., Torricelli, M., Calcaterra, R., Farina, C., PISANO, L., & Papini, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185493 · Cited by 12
“…anthro-pophilic species responsible for a wide range of fungal infections, including tinea pedis , tinea unguium , tinea cruris , tinea corporis , and tinea manuum [9]: predominantly, it affects individuals between the age of 20 and 60 with a tendency to infect older patients in recent years [16].”
BackgroundKaur, M., Singh, G., Shivgotra, R., et al. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02945-0 · Cited by 10
“It has been estimated that nearly a billion people over the globe suffer from dermatomycoses, or fungal infections of the nails, skin, and hair, making it one of the most predominant skin diseases [1, 2].”
El‐Bana, G. G., Abd-Elhalim, B. T., El-Sayed, A. F., & Abdel‐Ghani, G. E. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.140452 · Cited by 11
Elevating fungal care: bridging Brazil’s healthcare practices to global standards
Salmanton‐García, J., Falci, D. R., Cornely, O. A., Pasqualotto, A. C., Europe, I. D. A. T. C. T. B. A., Barth, A. L., Denning, D. W., Riera, F. O., Cimerman, S., Colombo, A. L., et al. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02112-24 · Cited by 13
“…pathogenic fungi (3), including Coccidioides spp., Histo plasma spp., Paracoccidioides spp., and Sporothrix spp. (3 –6), a significant rural workforce, and elevated rates of HIV/AIDS (4, 7–9), tuberculosis (10), malignancies (11), and solid organ (12) and hematopoietic stem cell transplantations.”
Self-citationIdentification of potential markers of elevated anticandidal activity of propolis extracts
Bollin, P., Kuś, P. M., Okińczyc, P., Dijck, P. V., & Szweda, P. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119799 · Cited by 13
Sahoo, B., Goyal, R., Dutta, S., Joshi, P., & Sanyal, K. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00079 · Cited by 15
Etiology of invasive candidosis agents in Russia: a multicenter epidemiological survey
Vasilyeva, N. V., Рудольфовна, Р. Е., Rudneva, M. V., Богомолова, Т. С., Taraskina, A. E., Fang, Y., Zhang, F., & Климко, Н. Н. (2018) · Frontiers of Medicine · doi:10.1007/s11684-017-0612-x · Cited by 16
Laser-Assisted Delivery of Molecules in Fungal Cells
McGraw, E., Dissanayaka, R., Vaughan, J. C., Kunte, N., Mills, G., Laurent, G. M., & Avila, L. A. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00720 · Cited by 9
Antifungal Activity of the Essential Oil of Echinops kebericho Mesfin: An In Vitro Study
Beressa, T. B., Deyno, S., & Alele, P. E. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/3101324 · Cited by 13
“6 million, similar to that of tuberculosis and over 3-fold more than malaria [6].”
BackgroundFungal Lysine Deacetylases in Virulence, Resistance, and Production of Small Bioactive Compounds
Bauer, I., & Graessle, S. (2021) · Genes · doi:10.3390/genes12101470 · Cited by 13
“For instance, aspergillosis infections by Aspergillus fumigatus affect more than 300,000 patients each year with mortality rates of 30–95% [11].”
BackgroundWhat ‘Omics can tell us about antifungal adaptation
Ribeiro, G. F., Denes, E., Heaney, H., & Childers, D. S. (2021) · FEMS Yeast Research · doi:10.1093/femsyr/foab070 · Cited by 11
“The incidence of invasive candidiasis is estimated at ∼5100 individuals per year in the UK and ∼25 000 patients per year in the USA, and in particular affects patients on intensive chemotherapy, immunosuppressive drugs or long-term hospital stays (Bongomin et al. 2017; Pegorie, Denning and Welfare 2017; Tsay et al. 20…”
BackgroundZhan, Y., Lu, C. C., Li, S., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.851891 · Cited by 10
“The most common pulmonary mycoses are Aspergillus, Candida, Cryptococcus species, and Pneumocystis jirovecii (Bongomin et al., 2017; Azoulay et al., 2019; Zhan et al., 2021).”
BackgroundNargesi, S., Valadan, R., Abastabar, M., Kaboli, S., Thekkiniath, J., & Hedayati, M. T. (2022) · Journal of Fungi · doi:10.3390/jof8101091 · Cited by 10
“Among the invasive fungal diseases (IFD), invasive aspergillosis (IA) is one of the most severe clinical entities, with mortality rates up to 70% in more than 300,000 cases estimated worldwide [2].”
BackgroundMartínez, O. I. C., Angulo-Ortíz, A., & Patiño, G. S. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11110 · Cited by 12
Ortíz, B., Aguilar, K., Galindo, C., Molina, L., & Fontecha, G. A. (2022) · Current Medical Mycology · doi:10.18502/cmm.8.3.11212 · Cited by 15
“with an annual prevalence of tens of millions of cases and mortality rates above 40% [4, 5].”
Wojciechowska, A., Janczak, J., Rytlewski, P., Sarewicz, M., Santos, A. C. F., Salgueiro, L., & Korabik, M. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.134776 · Cited by 10
A Review of Studies on Candida Species in Peninsular Malaysia
Farooq, H., Monowar, T., Latt, S. S., Chinni, S. V., Zainol, N. H., & Sabesan, G. S. (2022) · Advanced Biomedical Research · doi:10.4103/abr.abr_3_22 · Cited by 11
“2 Advanced Biomedical Research | 2022 With the rising prevalence of various species, Candida infections have also increased, with over 700,000 cases of invasive candidiasis annually worldwide, according to a global review on Candida published in 2017 by Bongomin et al.[13] According to that report, the highest rate of…”
BackgroundInfluentialChi, X., Xie, F., Li, L., Hao, Y., Wu, H., Li, X., Xia, G., Yan, L., Zhang, D., Jiang, Y., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106572 · Cited by 10
Clorgyline Analogs Synergize with Azoles against Drug Efflux in Candida auris
Toepfer, S., Lackner, M., Keniya, M. V., Zenz, L.-M., Friemert, M., Bracher, F., & Monk, B. C. (2023) · Journal of Fungi · doi:10.3390/jof9060663 · Cited by 11
“Invasive candidiasis is estimated to affect 750,000 patients annually [1], with intrinsic and acquired resistance limiting therapeutic options.”
BackgroundRahadjeng, E. R., Pratikto, H., Mukhlis, I., Restuningdiah, N., & Mala, I. K. (2023) · Journal of Social Economics Research · doi:10.18488/35.v10i4.3509 · Cited by 43
“Based on research (Bongomin, Gago, Oladele, & Denning, 2017), there are four measures of financial inclusion, namely: access, use, welfare, and quality.”
MethodFungal diversity and drug susceptibility of the oral mycobiome of domestic dogs
Esquivel, B. D., Salcido, E. M. R., Schweiker, A. M., Holder, B. L., KuKanich, B. K., KuKanich, K. S., & White, T. C. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2023.1281712 · Cited by 12
Machado, M. P., dos Santos, M. H., Guimarães, J. G., de Campos, G. Y., Brito, P. K. M. O., Ferreira, C. M. G., Rezende, C. P., Frota, N., Soares, S. G., Kumaresan, P. R., et al. (2023) · Bioengineered · doi:10.1080/21655979.2023.2281059 · Cited by 10
“The genus Cryptococcus spp. is one of the major pathogens responsible for invasive fungal infections [48].”
Background
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.